Krystal Biotech buy Guggenheim
Start price
27.02.24
/
50%
€152.00
Target price
27.02.25
€161.18
Performance (%)
14.14%
End price
28.02.25
€173.50
Summary
This prediction ended on 28.02.25 with a price of €173.50. The BUY prediction by Guggenheim finished with a performance of 14.14%. Guggenheim has a follow-up prediction for Krystal Biotech where he still thinks Krystal Biotech is a Buy. Guggenheim has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Krystal Biotech | -12.836% | -12.836% | -27.068% |
| iShares Core DAX® | 0.683% | 0.785% | 38.055% |
| iShares Nasdaq 100 | -1.457% | 3.734% | 23.153% |
| iShares Nikkei 225® | 0.931% | 2.958% | 11.220% |
| iShares S&P 500 | -2.022% | 2.444% | 15.543% |
Comments by Guggenheim for this prediction
In the thread Krystal Biotech diskutieren
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $130.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
In the thread Trading Krystal Biotech
Die von Guggenheim gewählte maximale Laufzeit wurde überschritten
Current prediction by Guggenheim for Krystal Biotech
Krystal Biotech
Start price
Target price
Perf. (%)
€120.90
07.05.25
07.05.25
€166.60
07.05.26
07.05.26
-3.39%
07.08.25
07.08.25
